Cardiff Oncology (CRDF) Accumulated Expenses (2011 - 2026)

Cardiff Oncology has reported Accumulated Expenses for 15 years, with the latest figure at $2.4 million in Q4 2025.

• Quarterly Accumulated Expenses fell 69.23% year-over-year to $2.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.4 million (down 69.23% YoY) and the FY2025 annual result came in at $2.4 million, down 69.23% from the prior year.
• Accumulated Expenses declined to $2.4 million in Q4 2025 per CRDF's latest filing, from $11.5 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $11.5 million in Q3 2025 and troughed at $2.4 million in Q4 2025.
• A 5-year average of $6.1 million and a median of $6.0 million in 2022 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2025: Accumulated Expenses soared 74.81% in 2022, then sank 69.23% in 2025.
• Over 5 years, Accumulated Expenses stood at $4.5 million in 2021, then rose by 14.36% to $5.2 million in 2022, then surged by 50.34% to $7.8 million in 2023, then increased by 1.46% to $7.9 million in 2024, then tumbled by 69.23% to $2.4 million in 2025.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $2.4 million, $11.5 million, and $9.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.